10-Q quarterly report · filed Nov 6, 2026

GYRE THERAPEUTICS, INC. (GYRE) Q3 2026 10-Q Quarterly Report

Short answer

GYRE THERAPEUTICS, INC. (GYRE) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $33M (up 7.8% year over year) with net income of −$3M.

Q3 2026 key financials · XBRL

Revenue
$33M
+7.8% YoY · +6.2% QoQ
Net income
−$3M
−142.4% YoY · +89.1% QoQ
Operating margin
-4.6%
EPS (diluted)
−$0.03
−200.0% YoY · +81.3% QoQ

Source: XBRL data from the GYRE THERAPEUTICS, INC. (GYRE) Q3 2026 10-Q on SEC EDGAR. USD.

GYRE THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $32.9M, up $0.2M or 1% YoY, driven by ETUARY sales despite lower Contiva and Etorel revenue
  • Operating loss $1.5M vs operating income $1.5M YoY, operating margin (4.6%) vs 4.6%
  • ETUARY best performer, higher sales volumes; Contiva and Etorel worst, lower revenue after centralized procurement
  • Cash and equivalents $41.6M vs $49.2M, operating cash outflow $17.5M for nine months
  • F351 NDA decision expected by end-2026 or Q1 2027, with Cullgen integration and clinical spending as headwinds

Risk Factors

  • No material changes from the Annual Report and Q2 Quarterly Report risk factors
  • Undisclosed risks: unknown or currently immaterial factors could materially adversely affect results
  • Clinical-stage business risk: carried-forward Annual Report and Q2 Quarterly Report risks remain applicable
  • Regulatory risk: carried-forward SEC-disclosed risks could materially affect financial position

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other GYRE THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.